Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality.
Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory …

One of the main causes of acute respiratory distress syndrome in coronavirus disease 2019
(COVID-19) is cytokine storm, although the exact cause is still unknown. Umbilical cord …

No effective drug treatments are available for coronavirus disease 2019 (COVID-19). Host-
directed therapies targeting the underlying aberrant immune responses leading to …

Background Acute respiratory distress syndrome (ARDS) is the devastating complication of
the new COVID-19 pandemic, directly correlated with releasing large amounts of …

There are no specific drug therapies or vaccines for the pandemic of coronavirus disease
2019 (COVID-19), which is associated with substantial mortality. Attenuating or reversing the …

Background Acute respiratory distress syndrome (ARDS) is a fatal complication of
coronavirus disease 2019 (COVID-19). There are a few reports of allogeneic human …

Objectives We aim to explore the safety and feasibility of umbilical cord mesenchymal stem
cells (UC‐MSCs) transplantation in patients with severe and critically severe coronavirus …

Background COVID-19 is a highly infectious respiratory disease. No therapeutics have yet
been proven effective for treating severe COVID-19. Objectives To determine whether …

Abstract Treatment of severe Coronavirus Disease 2019 (COVID-19) is challenging. We
performed a phase 2 trial to assess the efficacy and safety of human umbilical cord …

Background The long-term consequences of human umbilical cord-derived mesenchymal
stem cell (UC-MSC) treatment for COVID-19 patients are yet to be reported. This study …